Medtronic CEO Omar Ishrak says he'd acquire Ardian and CoreValve again, despite the high-profile failure of a clinical trial for Ardian's Symplicity renal denervation device and a CoreValve settlement with Edwards Lifesciences that could end up costing more than $1 billion.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1i4iYMg
Cap comentari:
Publica un comentari a l'entrada